Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Table 6 Inter-laboratory performance results

Study outline	Design	Results, % (95 % CI)
Inter-laboratory reproducibility (NSCLC) (n = 3 labs, 2 pathologists per lab) Each case tested 5 separate times	14 cases 7 PD-L1 high 7 PD-L1 low/negative	PPA 93.3 (89.0–95.9) NPA 79.5 (73.6–84.4) OPA 86.4 (82.7–89.3)
Inter-laboratory reproducibility (HNSCC) (n = 3 labs, 2 pathologists per lab) Each case tested 5 separate times	14 cases 7 PD-L1 high 7 PD-L1 low/negative	PPA 89.4 (84.4–92.9) NPA 99.5 (97.3–99.9) OPA 94.5 (91.8–96.3)

HNSCC head and neck squamous cell carcinoma, NPA negative percentage agreement, NSCLC non-small cell lung cancer, OPA overall percentage agreement, PPA positive percentage agreement

ISSN: 1746-1596